Novel Stannic Protoporfin Compositions, Methods of Making, and Uses Thereof
Novel Stannic protoporfin compositions exhibiting high purity and other characteristics, including a novel solubility profile and visual indicators suggesting increase pharmacological activity, including enhanced antiviral activity. Also disclosed are novel processes for making Stannic protoporfin according to a process that requires fewer steps than known processes.
1 . A stannic protoporfin composition comprising a compound of Formula (I)
wherein the composition comprises a total level of impurities of 1.5% or less, as measured by gas chromatography.
2 . The composition of claim 1 , wherein the total level of impurities is 1% or less.
3 . The composition of claim 1 , wherein the total level of impurities in the range of 0.1 to 1%.
4 . The composition of claim 1 , wherein the total level of impurities in the range of 0.4 to 1% or less.
5 . A method of making Stannic protoporfin comprising the steps of:
(a) dissolving hemin in hot formic acid to form a first intermediate composition;
(b) adding iron powder to the first intermediate composition to form a second intermediate composition;
(c) adding a filtrate of the second intermediate composition to an aqueous solution of NH 4 OAc to precipitate a third intermediate composition;
(d) dissolving the third intermediate composition in pyridine at an elevated temperature to form a fourth intermediate composition;
(e) filtering the fourth intermediate composition to form a filtrate; and
(f) precipitating a first intermediate compound according to Formula II:
6 . The method of claim 6 , further comprising adding the compound of Formula (II) to a mixture of stannous chloride, pyridine and glacial acetic acid to make a stannic protoporfin according to Formula I:
7 . The method of claim 6 , wherein adding the compound of Formula (II) to a mixture of stannous chloride, pyridine and glacial acetic acid is conducted in an inert environment.
8 . A stannic protoporfin composition made according to the process of claim 7 .
9 . A pharmaceutical composition comprising the stannic protoporfin composition of claim 1 and an iron pharmaceutical composition comprising: iron sucrose; bicarbonate; and a pharmaceutically acceptable aqueous carrier, wherein the iron sucrose is present in pharmaceutically effective amount, the iron being present in both iron (II) and iron (III) form, the pharmaceutical composition has a pH greater than 9, a concentration of iron (II) of 0.05% w/v to 0.41% w/v, and the iron sucrose has a MW according to GPC of between 33,000 and 38,000 Daltons.
10 . A pharmaceutical composition comprising the stannic protoporfin composition of claim 8 and an iron pharmaceutical composition comprising: iron sucrose; bicarbonate; and a pharmaceutically acceptable aqueous carrier, wherein the iron sucrose is present in pharmaceutically effective amount, the iron being present in both iron (II) and iron (III) form, the pharmaceutical composition has a pH greater than 9, a concentration of iron (II) of 0.05% w/v to 0.41% w/v, and the iron sucrose has a MW according to GPC of between 33,000 and 38,000 Daltons.
11 . A method of reducing post operative complications of a human patient from injury based on a scheduled or anticipated insult comprising administering to the patient the composition of claim 9 .
12 . A method of reducing post operative complications of a human patient from injury based on a scheduled or anticipated insult comprising administering to the patient the composition of claim 10 .